CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …

Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …

Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major
depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the …

Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and
response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging …

Precision medicine is an integrative approach to cardiovascular disease prevention and
treatment that considers an individual's genetics, lifestyle, and exposures as determinants of …

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum
concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 …

Objectives The aim of this study was to examine the effect of CYP2C19 genotype on clinical
outcomes in patients with coronary artery disease (CAD) who predominantly underwent …

Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

The interindividual genetic variations in drug metabolizing enzymes and transporters
influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision …

Cytochromes P450s (CYPs) constitute a superfamily of enzymes that catalyze the
metabolism of drugs and other substances. Endogenous substrates of CYPs include …